Rznomics Inc.
PublicRznomics Inc. is now publicly traded
The data on this page reflects Rznomics Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
VC Round
Dec 23, 2023
Est. Valuation at Exit
$100.07M
Total Funding Raised
$55.59M
Company Overview
Rznomics Inc. has raised $55.59M. It was founded in 2017.
Rznomics Inc. is a clinical-stage biopharmaceutical company that develops RNA-based gene therapies for cancers and intractable diseases using its proprietary trans-splicing ribozyme platform.
AI Layer
Non-AI
Rznomics Inc. Comparables
Compare Rznomics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| エディットフォース株式会社 | 76% | |
| Autotelic Bio | 71% | |
| Ethonova | 63% |
For institutional investors. Book with your work email.
Rznomics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 23, 2023 | ||||
| Series C | Jun 7, 2022 | ||||
| Series A | Sep 20, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Rznomics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shinhan Venture Investment | Series C |
| UTC Investment | Series C |
| KB Investment | VC Round |
| Synergy IB Investment | Series A |
| QUAD Investment Management | Series A |
| IBK Capital | Series C |
| LSK Investment | Series A |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 25, 2026
Rznomics is developing RNA-based gene therapies using its proprietary trans-splicing ribozyme platform, which is designed to enable precise RNA editing, in California.
- partners_withAug 24, 2026
Rznomics partners with Lilly Group in California to accelerate RNA therapeutics, including candidate discovery and development across more than 200 disease targets.
For institutional investors. Book with your work email.
Rznomics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.